Table 1.
Baseline and disease characteristics by dosing group
| Part A | Part B | Total (n = 33) | |||||
|---|---|---|---|---|---|---|---|
| 0.3 mg/kg (n = 4) | 1 mg/kg (n = 3) | 3 mg/kg (n = 7) | 10 mg/kg (n = 5) | 10 mg/kg without oral iron (cohort B1) (n = 7) | 10 mg/kg with oral iron (cohort B2) (n = 7) | ||
| Age, years | 64.5 (58–75) | 76.7 (63–88) | 62.1 (44–78) | 63.2 (53–75) | 66.3 (50–79) | 62.7 (51–72) | 64.9 (44–88) |
| Sex | |||||||
| Men | 2 (50) | 2 (67) | 3 (43) | 2 (40) | 3 (43) | 1 (14) | 13 (39) |
| Women | 2 (50) | 1 (33) | 4 (57) | 3 (60) | 4 (57) | 6 (86) | 20 (61) |
| Race | |||||||
| White | 4 (100) | 3 (100) | 5 (71) | 3 (60) | 5 (71) | 5 (71) | 25 (76) |
| Black or African American | 0 | 0 | 2 (29) | 1 (20) | 2 (29) | 2 (29) | 7 (21) |
| Asian | 0 | 0 | 0 | 1 (20) | 0 | 0 | 1 (3) |
| ECOG performance status | |||||||
| 0 | 1 (25) | 1 (33) | 2 (29) | 0 | 0 | 0 | 4 (12) |
| 1 | 3 (75) | 2 (67) | 3 (43) | 5 (100) | 7 (100) | 6 (86) | 26 (79) |
| 2 | 0 | 0 | 2 (29) | 0 | 0 | 1 (14) | 3 (9) |
| Prior cancer treatment | |||||||
| Systemic chemotherapy | 4 (100) | 3 (100) | 7 (100) | 5 (100) | 5 (71) | 4 (57) | 28 (85) |
| Radiotherapy | 1 (25) | 1 (33) | 2 (29) | 3 (60) | 2 (29) | 5 (71) | 14 (42) |
| Surgery | 3 (75) | 1 (33) | 2 (29) | 2 (40) | 1 (14) | 2 (29) | 11 (33) |
| Median no. of prior oncology treatments | 9.5 | 4.0 | 6.0 | 5.0 | 2.0 | 1.5 | 4.5 |
| Mean serum hepcidin (ng/mL) | 24.9 (18.51) | 12.2 (8.48) | 36.4 (21.87) | 51.1 (39.81) | 45.4 (20.23) | 39.7 (38.99) | 37.6 (28.46) |
| Mean hemoglobin (g/dL) | 9.1 (1.45) | 8.9 (0.91) | 8.5 (0.83) | 9.8 (0.84) | 9.4 (1.13) | 9.5 (0.31) | 9.2 (0.95) |
| Mean erythropoietin (mIU/mL) | 141.3 (92.71) | 42.0 (20.16) | 103.2 (135.14) | 94.4 (116.49) | 70.0 (60.87) | 46.1 (25.67) | 81.8 (88.29) |
| Mean serum ferritin (μg/L) | 779.0 (303.64) | 237.2 (136.68) | 667.1 (683.65) | 263.7 (178.90) | 714.6 (553.58) | 289.0 (175.70) | 510.3 (464.15) |
| Cancer type | |||||||
| Multiple myeloma | 1 (25) | 0 | 2 (29) | 3 (60) | 3 (43) | 3 (43) | 14 (42) |
| Breast cancer | 0 | 0 | 0 | 1 (20) | 3 (43) | 0 | 4 (12) |
| Othera | 3 (75) | 3 (100) | 5 (71) | 1 (20) | 1 (14) | 4 (57) | 15 (46) |
Values shown are for the safety population (i.e., all patients who received at least one dose of LY2787106 [n = 33]). Data are mean (range) for age; median for number of prior oncology treatments; mean (SD) for serum hepcidin, hemoglobin, erythropoietin, and serum ferritin; and n (%) for all other parameters
ECOG Eastern Cooperative Oncology Group
a“Other” cancer types include Waldenstrom’s macroglobulinemia (2 patients), pancreatic adenocarcinoma (2 patients), rectal cancer (2 patients), renal cell carcinoma, metastatic prostate cancer, colon adenocarcinoma, unknown primary presumed ovarian adenocarcinoma, metastatic sarcomatoid carcinoma of the distal esophagus, non-small cell lung cancer, adenocarcinoma of lung, gastrointestinal stromal tumor, and adenocarcinoma of the liver